Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Fostamatinib in IgA Nephropathy
2014-000331-16Phase 2Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fostamatinib in IgA nephropathy (IgAN) (3 arms), sponsored by Rigel Pharmaceuticals, Inc. Primary endpoint: Change in proteinuria (sPCR) at 24 weeks. Started May 2014; status: completed.
02
Drugs
fostamatinib
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2014-000331-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000331-16.